Harry Wilmerding
Novavax announced on Monday that its two-dose COVID-19 vaccine is 90% effective, according to a press release on Novavax’s website.
The phase-3 trial enrolled 29,960 participants ages 18 and older in the U.S. and Mexico. The study found that 77 of the participants tested positive for COVID-19, with 63 testing positive in the placebo group and 14 in the vaccine group, according to the press release.
“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection,” Stanley C. Erck, President, and CEO of Novavax said in the press release.
“Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines,” Erck said.
Novavax intends to file for approval from the Food And Drug Administration in the third quarter once additional testing is completed, according to the press release.
Upon approval, Novavax said it plans to make 100 million doses per month by the end of the third quarter and 150 million per month by the end of the fourth quarter, the company said.
The company said that the vaccine was “generally well tolerated” with common side effects, including pain near the injection, fatigue, muscle pain, and headaches.
The vaccine also saw 100% effectiveness against moderate and severe disease, 93.2% against variants of concern, and 91% against high-risk populations, the company said.
Vaccine trials for ages 12-17 are in progress, the company said.
Android Users, Click Here To Download The Free Press App And Never Miss A Story. It’s Free And Coming To Apple Users Soon.
Support journalism by clicking here to our gofundme or sign up for our free newsletter by clicking here